Ironwood Pharmaceuticals (IRWD) Cash from Financing Activities (2010 - 2025)

Ironwood Pharmaceuticals has disclosed Cash from Financing Activities across 16 years of filings, most recently posting $122000.0 for Q4 2025.

• Cash from Financing Activities for Q4 2025 came in at $122000.0, up 100.82% year-over-year; the trailing twelve-month figure through Dec 2025 was $216000.0 (up 100.2% YoY), and the FY2025 annual result was $216000.0, up 100.2% from the prior year.
• Cash from Financing Activities came in at $122000.0 for Q4 2025 at Ironwood Pharmaceuticals, up from $88000.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $399.1 million in Q2 2023 to a low of -$150.3 million in Q2 2022.
• The 5-year median for Cash from Financing Activities is $6000.0 (2025), against an average of -$3.8 million.
• Across the five-year window, Cash from Financing Activities jumped 820.0% in 2021 and slumped 9508.78% in 2023, its largest moves.
• Ironwood Pharmaceuticals' Cash from Financing Activities stood at -$18.6 million in 2021, then jumped by 115.1% to $2.8 million in 2022, then tumbled by 1914.11% to -$50.9 million in 2023, then surged by 70.75% to -$14.9 million in 2024, then surged by 100.82% to $122000.0 in 2025.
• The last three Cash from Financing Activities figures came in at $122000.0 (Q4 2025), $88000.0 (Q2 2025), and $6000.0 (Q1 2025), per Business Quant data.